The Colposcope+, our first product, is a non-invasive device enabling early detection of cervical cancer. Of the 87 million office visits women make to gynecologists every year in the US, 55 million are administered a Pap smear, and 4 million are referred to a follow up colposcopy. The colposcopy market is fragmented, with a dozen companies offering devices with very low specificity (~0.5) – resulting in the need for multiple biopsies that can be avoided, reducing risk to women’s reproductive health. Better imaging could meet this market need for the 43,000 gynecologists in the US at 12,700 locations. MobileODT is taking an ‘incremental market entry’ approach, focused on building a competitively priced colposcope (the primary device used in cervical cancer imaging), with upgraded optical components and a powerful algorithm analyzing images acquired. MobileODT will release additional ‘features’ and add-ons for this colposcope on an annual basis, enabling full spectroscopy, Optical Coherence Tomography (OCT), and multi-modal image processing. MobileODT will sell a proprietary disposable for calibration of the device.
